Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia

Kou Gi Shyu, Hang Chang, Bao Wei Wang, Peiliang Kuan

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.

Original languageEnglish
Pages (from-to)85-92
Number of pages8
JournalAmerican Journal of Medicine
Volume114
Issue number2
DOIs
Publication statusPublished - Feb 1 2003
Externally publishedYes

Fingerprint

Genetic Therapy
Vascular Endothelial Growth Factor A
Leg
Ischemia
Extremities
Brachial Artery
Peripheral Arterial Disease
Ankle
Ulcer
Blood Pressure
Safety
Pain
Muscles
Genes
Therapeutics

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. / Shyu, Kou Gi; Chang, Hang; Wang, Bao Wei; Kuan, Peiliang.

In: American Journal of Medicine, Vol. 114, No. 2, 01.02.2003, p. 85-92.

Research output: Contribution to journalArticle

Shyu, Kou Gi ; Chang, Hang ; Wang, Bao Wei ; Kuan, Peiliang. / Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. In: American Journal of Medicine. 2003 ; Vol. 114, No. 2. pp. 85-92.
@article{09950982dd3044b08e5315f9ea85390f,
title = "Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia",
abstract = "PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.",
author = "Shyu, {Kou Gi} and Hang Chang and Wang, {Bao Wei} and Peiliang Kuan",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0002-9343(02)01392-X",
language = "English",
volume = "114",
pages = "85--92",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia

AU - Shyu, Kou Gi

AU - Chang, Hang

AU - Wang, Bao Wei

AU - Kuan, Peiliang

PY - 2003/2/1

Y1 - 2003/2/1

N2 - PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.

AB - PURPOSE: We sought to investigate the safety and efficacy of intramuscular gene therapy with vascular endothelial growth factor (VEGF) in patients with chronic critical leg ischemia. METHODS: Gene transfer was performed in 24 limbs of 21 patients with rest pain, some of whom also had nonhealing ischemic ulcers (n = 16) due to occlusive peripheral arterial disease. Between 400 μg and 2000 μg of phVEGF165 (400 μg, n = 2; 800 μg, n = 4; 1200 μg, n = 4; 1600 μg, n = 6; and 2000 μg, n = 8) was injected directly into the muscles of the ischemic limb; the same dose was injected 4 weeks later. The ratio of blood pressures at the ankle and brachial artery was measured before and after treatment. RESULTS: Mean (± SD) plasma levels of VEGF increased significantly from 26 ± 31 pg/mL to 63 ± 56 pg/mL (P 165 for patients with chronic critical leg ischemia is safe, feasible, and effective.

UR - http://www.scopus.com/inward/record.url?scp=0037313811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037313811&partnerID=8YFLogxK

U2 - 10.1016/S0002-9343(02)01392-X

DO - 10.1016/S0002-9343(02)01392-X

M3 - Article

VL - 114

SP - 85

EP - 92

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -